Reviewer’s report

Title: Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications. A review.

Version: 2 Date: 3 January 2014

Reviewer: Wayman Cheatham

Reviewer’s report:

Please number your comments and divide them into:

- Major Compulsory Revisions

None

- Minor Essential Revisions

1) Under “PPAR ligands” – correct the spelling of “thiazolidinediones”. The author omits the “h” in this term here AND under the topical heading of “PPAR# pharmacological agonists”

2) In the topical heading “Natural agonist of PPAR#”, the term “agonist” should be pleural. i.e. “Natural agonists of PPAR#”

3) Under “Natural agonist of PPAR#”, the second paragraph begins with the term “Despite”. Did the author intend to use the phrase “In addition to …” rather than “Despite” here?

4) Under “PPAR# pharmacological agonists”, where the therapeutic agents are first named, “troglitazone” should also be mentioned along with “rosiglitazone” and “pioglitazone”. While troglitazone was withdrawn from the market due to hepatotoxicity, the topical elucidation of the historical agents would only be complete if troglitazone were mentioned when the class is first introduced.

5) Also, under “PPAR# pharmacological agonists”, the term “hemoglobin” is anglicized as “haemoglobin”. The American spelling of “hemoglobin” should be used.

- Discretionary Revisions

1) Might the author wish to change the construct of the main title to: “Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review” (note the suggested use of a hyphen between the last third and second words rather than a period)

Quality of written English: Needs some language corrections before being published
Statistical review: No, the manuscript does not need to be seen by a statistician.